FREE SHIPPING BOTH WAYS

ON EVERY ORDER!

LIST PRICE:

$71.40

Sorry, this item is currently unavailable.

ISBN: 9780853699804 | 0853699801

Edition: 2ndFormat: Paperback

Publisher: PHARMACEUTICAL PRESS

Pub. Date: 4/1/2012

Because Knetbooks knows college students. Our rental program is designed to save you time and money. Whether you need a textbook for a semester, quarter or even a summer session, we have an option for you. Simply select a rental period, enter your information and your book will be on its way!

- We have the lowest prices on thousands of popular textbooks
- Free shipping both ways on ALL orders
- Most orders ship within 48 hours
- Need your book longer than expected? Extending your rental is simple
- Our customer support team is always here to help

Basic Pharmacokinetics provides an understanding of the principles of pharmacokinetics and biopharmaceutics and of how these principles can be applied to achieve successful drug therapy.

Sunil S Jambhekar is Professor and Associate Dean, LECOM-Bradenton School of Pharmacy, Florida, USA. Phillip J Breen is Associate Professor of Pharmaceutics, Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, USA.

Preface | p. xi |

About the authors | p. xiii |

Introduction and overview | p. 1 |

Use of drugs in disease states | p. 1 |

Important definitions and descriptions | p. 2 |

Sites of drug administration | p. 4 |

Review of ADME processes | p. 5 |

Pharmacokinetic models | p. 7 |

Rate processes | p. 12 |

Mathematical review | p. 17 |

Introduction | p. 17 |

A brief history of pharmacokinetics | p. 18 |

Hierarchy of algebraic operations | p. 18 |

Exponents and logarithms | p. 18 |

Variables, constants, and parameters | p. 19 |

Significant figures | p. 20 |

Units and their manipulation | p. 21 |

Slopes, rates, and derivatives | p. 21 |

Time expressions | p. 24 |

Construction of pharmacokinetic sketches (profiles) | p. 25 |

Intravenous bolus administration (one-compartment model) | p. 29 |

Introduction | p. 29 |

Useful pharmacokinetic parameters | p. 30 |

The apparent volume of distribution (V) | p. 32 |

The elimination half life (t_{1/2}) | p. 36 |

The elimination rate constant (K or K_{el}) | p. 38 |

Plotting drug concentration versus time | p. 40 |

Intravenous bolus administration of drugs: summary | p. 41 |

Intravenous bolus administration: monitoring drug in urine | p. 42 |

Use of urinary excretion data | p. 43 |

Clearance concepts | p. 55 |

Introduction | p. 55 |

Clearance definitions | p. 56 |

Clearance: rate and concentration | p. 58 |

Clearance: tank and faucet analogy | p. 58 |

Organ clearance | p. 60 |

Physiological approach to clearance | p. 61 |

Estimation of systemic clearance | p. 65 |

Calculating renal clearance (Cl_{r}) and metabolic clearance (cl_{m}) | p. 66 |

Determination of the area under the plasma concentration versus time curve: application of the trapezoidal rule | p. 67 |

Elimination mechanism | p. 69 |

Use of creatinine clearance to determine renal function | p. 69 |

Recently developed equations for estimating creatinine clearance and glomerular filtration rate | p. 76 |

Problem set 1 | p. 79 |

Drug absorption from the gastrointestinal tract | p. 95 |

Gastrointestinal tract | p. 95 |

Mechanism of drug absorption | p. 98 |

Factors affecting passive drug absorption | p. 100 |

pH-partition theory of drug absorption | p. 101 |

Extravascular routes of drug administration | p. 105 |

Introduction | p. 106 |

Drug remaining to be absorbed, or drug remaining at the site of administration | p. 106 |

Determination of elimination half life (t_{1/2}) and elimination rate constant (K or K_{el}) | p. 109 |

Absorption rate constant (K_{a}) | p. 110 |

Wagner-Nelson method (one-compartment model) and Loo-Riegelman method (two-compartment model) | p. 111 |

Lag time (t_{0}) | p. 115 |

Some important comments on the absorption rate constant | p. 116 |

The apparent volume of distribution (V) | p. 116 |

Time of maximum drug concentration, peak time (t_{max}) | p. 117 |

Maximum (peak) plasma concentration (C_{p})_{max} | p. 118 |

Some general comments | p. 120 |

Example for extravascular route of drug administration | p. 121 |

Flip-flop kinetics | p. 126 |

Problem set 2 | p. 127 |

Bioavailability/bioequivalence | p. 137 |

Introduction | p. 138 |

Important definitions | p. 138 |

Types of bioavailability | p. 139 |

Bioequivalence | p. 141 |

Factors affecting bioavailability | p. 141 |

The first-pass effect (presystemic clearance) | p. 142 |

Determination of the area under the plasma concentration-time curve and the cumulative amount of drug eliminated in urine | p. 143 |

Methods and criteria for bioavailability testing | p. 145 |

Characterizing drug absorption from plasma concentration versus time and from urinary data following the administration of a drug via different extravascular routes and/or dosage forms | p. 155 |

Equivalency terms | p. 157 |

Food and Drug Administration codes | p. 157 |

Fallacies on bioequivalence | p. 158 |

Evidence of generic bioinequivalence or of therapeutic inequivalence for certain formulations approved by the FDA | p. 159 |

Problem set 3 | p. 161 |

Factors affecting drug absorption: Physicochemical factors | p. 175 |

Dissolution rate | p. 175 |

Dissolution process | p. 175 |

Noyes-Whitney equation and drug dissolution | p. 176 |

Factors affecting the dissolution rate | p. 177 |

Gastrointestinal absorption: Role of the dosage form | p. 187 |

Introduction | p. 187 |

Solution (elixir, syrup, and solution) as a dosage form | p. 188 |

Suspension as a dosage form | p. 188 |

Capsule as a dosage form | p. 189 |

Tablet as a dosage form | p. 189 |

Dissolution methods | p. 191 |

Formulation and processing factors | p. 191 |

Correlation of in vivo data with in vitro dissolution data | p. 194 |

Continuous intravenous infusion (one-compartment model) | p. 203 |

Introduction | p. 203 |

Monitoring drug in the body or blood (plasma/serum) | p. 205 |

Sampling drug in body or blood during infusion | p. 205 |

Sampling blood following cessation of infusion | p. 220 |

Use of post-infusion plasma concentration data to obtain half life, elimination rate constant and the apparent volume of distribution | p. 222 |

Rowland and Tozer method | p. 225 |

Problem set 4 | p. 227 |

Multiple dosing: Intravenous bolus administration | p. 237 |

Introduction | p. 237 |

Useful pharmacokinetic parameters in multiple dosing | p. 241 |

Designing or establishing the dosage regimen for a drug | p. 248 |

Concept of drug accumulation in the body (R) | p. 249 |

Determination of fluctuation (¿): intravenous bolus administration | p. 251 |

Number of doses required to reach a fraction of the steady-state condition | p. 254 |

Calculation of loading and maintenance doses | p. 254 |

Maximum and minimum drug concentration at steady state | p. 255 |

Multiple dosing: extravascular routes of drug administration | p. 257 |

Introduction | p. 257 |

The peak time in multiple dosing to steady state (t′_{max}) | p. 259 |

Maximum plasma concentration at steady state | p. 260 |

Minimum plasma concentration at steady state | p. 261 |

"Average" plasma concentration at steady state: extravascular route | p. 262 |

Determination of drug accumulation: extravascular route | p. 263 |

Calculation of fluctuation factor (¿) for multiple extravascular dosing | p. 264 |

Number of doses required to reach a fraction of steady state: extravascular route | p. 264 |

Determination of loading and maintenance dose: extravascular route | p. 265 |

Interconversion between loading, maintenance, oral, and intravenous bolus doses | p. 266 |

Problem set 5 | p. 271 |

Two-compartment model | p. 285 |

Introduction | p. 285 |

Intravenous bolus administration: two-compartment model | p. 287 |

Determination of the post-distribution rate constant (ß) and the coefficient B | p. 292 |

Determination of the distribution rate constant (¿) and the coefficient A | p. 292 |

Determination of micro rate constants: the inter-compartmental rate constants (K_{21} and K_{12}) and the pure elimination rate constant (K_{10}) | p. 295 |

Determination of volumes of distribution (V) | p. 296 |

How to obtain the area under the plasma concentration-time curve from time zero to time t and time ∞ | p. 298 |

General comments | p. 299 |

Example | p. 300 |

Further calculations to perform and determine the answers | p. 302 |

Extravascular dosing of a two-compartment model drug | p. 303 |

Problem set 6 | p. 305 |

Multiple intermittent infusions | p. 309 |

Introduction | p. 309 |

Drug concentration guidelines | p. 311 |

Example: determination of a multiple intermittent infusion dosing regimen for an aminoglycoside antibiotic | p. 311 |

Does to the patient from a multiple intermittent infusion | p. 313 |

Multiple intermittent infusion of a two-compartment drug: vancomycin "peak" at 1 hour post infustion | p. 313 |

Vancomycin dosing regimen problem | p. 314 |

Adjustment for early or late drug concentrations | p. 315 |

Problem set 7 | p. 319 |

Nonlinear pharmacokinetics | p. 323 |

Introduction | p. 323 |

Capacity-limited metabolism | p. 325 |

Estimation of Michaelis-Menten parameters (V_{max} and K_{m}) | p. 327 |

Relationship between the area under the plasma concentration versus time curve and the administered dose | p. 330 |

Time to reach a given fraction of steady state | p. 332 |

Example: calculation of parameters for phenytoin | p. 333 |

Problem set 8 | p. 337 |

Drug interactions | p. 341 |

Introduction | p. 341 |

The effect of protein-binding interactions | p. 342 |

The effect of tissue-binding interactions | p. 348 |

Cytochrome P450-based drug interactions | p. 349 |

Drug interactions linked to transporters | p. 355 |

Problem set 9 | p. 357 |

Pharmacokinetic and pharmacodynamic relationships | p. 359 |

Introduction | p. 359 |

Generation of a pharmacokinetic- pharmacodynamic (PKPD) equation | p. 361 |

Pharmacokinetic and pharmacodynamic drug interactions | p. 364 |

Problem set 10 | p. 367 |

Metabolite pharmacokinetics | p. 369 |

Introduction | p. 369 |

General model | p. 370 |

Single intravenous bolus of drug conforming to a one-compartment model | p. 370 |

Single oral dose of drug conforming to a one-compartment model | p. 382 |

Intravenous infusion of a one-compartment model parent drug | p. 384 |

Chronic dosing to steady state | p. 385 |

Study design required to obtain various metabolite pharmacokinetic parameters | p. 388 |

Computer-aided simulation and fitting of metabolite pharmacokinetic data | p. 388 |

Case in point: meperidine and normeperidine | p. 388 |

Active metabolites in renal dysfunction | p. 388 |

Sample metabolite pharmacokinetics calculations | p. 393 |

Pharmacokinetic data fitting | p. 395 |

Introduction | p. 395 |

Pharmacokinetic parameter determination | p. 395 |

Nonlinear regression | p. 397 |

Goodness of fit indices | p. 398 |

Ways to improve fit | p. 401 |

Evaluation of program output | p. 401 |

How are the values of the parameters determined? | p. 404 |

Problems that may occur during a nonlinear regression run | p. 407 |

Weighting of data points | p. 408 |

Simulation | p. 409 |

Initial estimates | p. 411 |

Conclusion | p. 412 |

Pharmacokinetics and pharmacodynamics of biotechnology drugs | p. 413 |

Introduction | p. 413 |

Proteins and peptides | p. 413 |

Monoclonal antibodies | p. 419 |

Oligonucleotides | p. 423 |

Vaccines (immunotherapy) | p. 424 |

Gene therapies | p. 425 |

p. 427 | |

Introduction | p. 427 |

Statistical moment theory | p. 428 |

Applications | p. 439 |

Glossary | p. 443 |

References | p. 453 |

Index | p. 461 |

Table of Contents provided by Ingram. All Rights Reserved. |